The AI Radiology Reimbursement Ladder

FDA clearance is not the finish line for AI radiology tools. 🚩
It is just stage two of a four-stage ladder most hospitals have never mapped out.

CMS just approved a New Technology Add-on Payment for Aidoc’s CARE Body CT Multi-Triage, effective October 1, 2026. According to EHRAtlas, the NTAP provides a three-year reimbursement pathway for qualifying Medicare Fee-for-Service inpatient cases.

That is a landmark moment. And it exposed exactly how broken most hospitals’ AI evaluation process is.

Here is the framework I call The AI Radiology Reimbursement Ladder.

🔷 Stage 1: Regulatory Foundation
The tool must receive FDA Breakthrough Device Designation before clearance. For CARE Body CT Multi-Triage, the FDA granted Breakthrough Device Designation in September 2025. Full clearance followed in January 2026. That roughly four-month window is faster than the traditional pathway, but it still requires intentional pursuit of breakthrough status, not a standard 510(k) alone.

🔷 Stage 2: FDA Clearance for Scope
Clearance is scoped. CARE Body CT Multi-Triage is FDA-cleared specifically to flag suspected findings on contrast and non-contrast CT studies of the chest, abdomen, and pelvis. Not every CT. Not every setting. Scoped clearance defines exactly what you can and cannot bill around later.

🔷 Stage 3: NTAP Eligibility
The NTAP program is CMS’s mechanism for bridging the gap between clearance and sustainable reimbursement. It applies only to eligible inpatient cases under Medicare Fee-for-Service. It does not cover outpatient imaging, does not apply to every hospital, and requires specific billing compliance. If your hospital skips the verification step, you either miss revenue or create audit exposure.

🔷 Stage 4: Scale Justification
This is where clinical volume matters. Aidoc’s technology is deployed in nearly 2,000 hospitals and has analyzed more than 150 million patient cases, according to EHRAtlas. Abdominal CT imaging alone represents more than 40% of CT imaging, according to DistilInfo. At that volume, even an add-on payment per eligible case compounds significantly across a health system. Without scale, the unit economics never close.

What hospitals get wrong is evaluating AI tools at Stage 1 or Stage 2 and assuming reimbursement will follow automatically.

It will not.

The NTAP decision took from September 2025 to August 2026 to finalize, even after the FDA clearance was in hand. That is an 11-month gap between clearance and the billing start date of October 1, 2026.

If your CFO is not modeling for that gap, your ROI projections are fiction.

The practical checklist before committing to any AI radiology tool:
– Does it have Breakthrough Device Designation or just a 510(k)?
– Is the FDA clearance scoped to your actual use case and setting?
– Has CMS or a major payer approved a reimbursement pathway, and for which site of service?
– What is the eligible volume at your facility under the specific qualifying criteria?
– Is your billing team prepared to operationalize the new code from day one?

The NTAP for CARE Body CT Multi-Triage is the first Medicare inpatient reimbursement precedent for AI CT triage. More will follow. But the hospitals that benefit will be the ones who already understand the ladder, not the ones still waiting on their vendor to explain it.

Worth saving if you are evaluating AI diagnostic tools for your imaging program this quarter.

👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com